VXRT - Vaxart shares rise 8% on promise of oral COVID vaccine against Omicron

Vaxart (VXRT +8.1%) shares are up today -- the third day in a row -- as the company continues to benefit from a plan to test the reactivity of its COVID-19 oral vaccine candidate against the Omicron variant. The company says that it will start two studies next month. One will use mucosal and serum samples from participants in its current phase 2 COVID oral vaccine trial. The other will be an animal challenge study to see how the phase 2 vaccine compares against an Omicron-specific oral vaccine under development. Vaxart says that its COVID vaccine's immunogenicity profile suggest it may be effective against multiple variants, including Omicron. Read why Seeking Alpha contributor Edmund Ingham is neutral on Vaxart.

For further details see:

Vaxart shares rise 8% on promise of oral COVID vaccine against Omicron